Predicting Reduction of Hypertension After Adrenalectomy for Primary

Status Completed

Clinical Trial Summary

Primary aldosteronism (PA) is the excessive endogenous production of the mineralocorticoid aldosterone. Although various rare forms of PA exist, the vast majority of cases are accounted by either an aldosterone-producing adenoma (APA) or bilateral adrenal hyperplasia. During the last decades the prevalence of PA has risen, predominantly due to better awareness of disease. Several studies estimated a prevalence of PA up to 17% in an unselected population of hypertensive patients. However, in a population with resistant hypertension the reported prevalence is even higher: 17-23%. This emphasizes the clinical impact of PA on morbidity and mortality due to high blood pressure. Since both hypertension and aldosteronism are independent risk factors for cardiovascular morbidity, the aim of treatment is curation or reduction of both. After an adrenalectomy for APA normalization of biochemical abnormalities is achieved in almost all cases. Nevertheless, curation of hypertension (systolic blood pressure <140 and diastolic blood pressure <90 mmHg) without the need of antihypertensive medication is accomplished in only 35-45% of the cases. In 2008 the Aldosteronoma Resolution Score (ARS) was developed. This score predicts the likelihood of complete resolution of the hypertension in patients with an aldosteronoma and has been validated by other investigator groups. Reduction of hypertension is also an important clinical outcome and is reported in 90-98% of the patients after surgery. In most studies reduction is defined as a certain decrease in blood pressure or antihypertensive medication. However, there is no consensus on the precise definition of reduction in these patients, which leads to incomparable results. The aim of the proposed study is to determine the proportion of patients with clinically relevant reduction of hypertension after adrenalectomy in a large cohort. Furthermore, the investigators aim to determine the characteristics predicting this clinically relevant reduction. Additionally, the investigators evaluate the predictive value of the Aldosteronoma Resolution Score for clinically relevant reduction and aim to develop a scoring system to help clinicians predict the likelihood of reduction of hypertension after adrenalectomy so it can be used for patient counseling.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Adenoma
Adrenocortical Adenoma
Hyperaldosteronism
Hypertension
Primary Aldosteronism
Primary Aldosteronism Due to Aldosterone Producing Adenoma
Primary Aldosteronism Due to Conn Adenoma

Clinical Trial Details

NCT number	NCT04761354
Study type	Observational
Source	UMC Utrecht
Contact
Status	Completed
Phase
Start date	March 26, 2016
Completion date	March 26, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02885662` - Study of CS-3150 in Patients With Primary Aldosteronism	N/A
Withdrawn	`NCT02096939` - Microvascular Function in Primary Aldosteronism	N/A
Completed	`NCT01728493` - Primary Aldosteronism in General Practice: Organ Damage, Epidemiology and Treatment	N/A
Recruiting	`NCT06228677` - Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization
Recruiting	`NCT06047912` - Screening for Primary Aldosteronism in Hypertension With 24-hour URinary aLdosterone
Recruiting	`NCT04991961` - Effect of Anti-hypertensive Medications on the Diagnostic Accuracy in Screening for Primary Aldosteronism
Recruiting	`NCT05501080` - The Effect of SAAE on Ventricular Remodeling in PA Patients	N/A
Recruiting	`NCT05405101` - Randomised Trial Comparing Thermal Ablation With Adrenalectomy in the Treatment of Unilateral Asymmetric PA	N/A
Recruiting	`NCT05973604` - Prevalence of Primary Aldosteronism in Atrial Fibrillation
Recruiting	`NCT05826080` - Effect of Adrenocorticotropic Hormone Stimulation During Adrenal Vein Sampling in Primary Aldosteronism
Completed	`NCT04179019` - Calcium Channel Blockade in Primary Aldosteronism	Phase 2
Completed	`NCT03500120` - Diagnostic Accuracy of Seated Saline Suppression Test for Primary Aldosteronism
Recruiting	`NCT04213963` - Prospective Study on Primary Aldosteronism in Resistant Hypertension
Completed	`NCT05435703` - Renal Cysts and Primary Aldosteronism
Recruiting	`NCT02945904` - IS Metomidate PET-CT Superior to Adrenal Venous Sampling in Predicting Outcome From Adrenalectomy in Patients With Primary Hyperaldosteronism
Enrolling by invitation	`NCT02257450` - Primary Aldosteronism in Malaysia: A Nationwide Multicentre Study	N/A
Recruiting	`NCT05561361` - The Effect of SAAE on Vascular Endothelial Function in PA Patients
Completed	`NCT03398785` - Adrenal Artery Ablation Treats Primary Aldosteronism	Phase 3
Recruiting	`NCT03224312` - Chongqing Primary Aldosteronism Study
Recruiting	`NCT04428827` - Outcome of Patients With Primary Aldosteronism

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Predicting Reduction of Hypertension After Adrenalectomy for Primary Aldosteronism: a Multicenter Analysis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms